Program Overview (5 min)
Novel Therapies for Relapsed/Refractory HER2 MBC (30 min)
- New anti-HER2-directed antibody–drug conjugates
- Future directions for antibody-based therapies for HER2-positive breast cancer
Case Discussions: Management of Relapsed/Refractory HER2 MBC Today (20 min)
- Selecting treatment for patients HER2-positive MBC following relapse on traditional HER2 targeted agents
- Selecting treatment for patients with previously treated HER2-positive MBC and CNS metastases
Question and Answer Session (5 min)
Adam Brufsky, MD
Professor of Medicine
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania USA
Thomas Bachelot, MD, PhD
Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Centre Leon Bérard
Cristina Saura, MD, PhD
Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Vall d’Hebrón University Hospital
The goal of this activity is to improve the knowledge, competence and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.
This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.
- Integrate recent practice-changing advances in the treatment of HER2-positive MBC
- Identify new and emerging therapies for third line and beyond for HER2-positive MBC
- Assess clinical trial results for novel HER2-directed and targeted therapies in this setting
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.